Bookmark and Share

Last Minute:          For more news, click here.

Authentication
       
       
Remember me? 

Rise of
+3.85 (+1.24%) Biogen Idec Inc. - [Ticker: BIIB]Chart Biogen Idec Inc.  News Biogen Idec Inc.  Download Historical Prices for Metastock Biogen Idec Inc. and Others  Technical Analysis Biogen Idec Inc.  
Last Trade315.51Last Trade Time2017-11-01 - 19:35:00
Variation+3.85 (+1.24%)Open312.75
High319.95Low311.57
Volume1,047,609Average Volume (3m)0
YieldBid / Ask315.47 x 300 - 315.59 x 200
Former Close311.6652 Week Range[0.00 - 0.00]
PER0.00%EPS0.00
Ex-Dividend DateDividend Payment
Market Capitalization0 1 Year Price-Target0.00
Note: The data may have some minutes of delay.
Watch more quotes

Intraday   5 days   1 month   3 months   6 months   1 year   2 years   5 years   10 years            Use this chart on your website!
Biogen Idec Inc. -  [Ticker: BIIB] chart
Change to Biogen Idec Inc. Interactive Technical Analysis Chart

Last 10 Forum Topics about Biogen Idec Inc.:
No topics about Biogen Idec Inc. [BIIB] have been found, but a search on the Forum for more topics related to Biogen Idec Inc. is advised.

 News about Biogen Idec Inc. [BIIB]:   (ordered by relevance)
Biogen Alzheimer's Drug Shows Brain Swelling In 35% Of Patients  Benzinga Where Biogen Stands With Analysts - Benzinga  Benzinga Is Biogen Inc (BIIB) a Stock to Watch After Losing -3.00% This Week?  InvestorsObserver Biogen (BIIB) Stock Rises After Reporting Positive Data in Phase 3 Alzheimer's Trial  InvestorsObserver Will Biogen Stock Rise After The Recent 6% Fall?  Forbes Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst - Benzinga  Benzinga Biogen Stock To See Much Higher Levels After A 38% Rise Yesterday  Forbes UPDATE: Biogen Shares Halted Ahead Of FDA Decision On Co.'s Alzheimer's Candidate, Aducanumab Monday  Benzinga Here?s Why Biogen Stock Can Offer Over 35% Gains  Forbes Biogen Alzheimer's Drug Wins Historic Approval, but FDA Requires New Trial  Genetic Engineering & Biotechnology News Biogen Drops Idec From Name  Wall Street Journal Biogen Idec Becomes Biogen  Business Wire Biogen Inc. Common Stock (BIIB) Stock Price, Quote, News & History  Nasdaq Biogen Stock: With Alzheimer's Treatment In FDA Court, Is BIIB Stock A Buy In January 2021?  Investor's Business Daily Bleeding Disorders Treatment Market Generic Products To Be The Growth Factor For This Market  Medgadget Biogen pushes back against critics of Alzheimer's drug as early sales hit $2mln  ZAWYA Biogen bats aside Aduhelm jitters with confident third quarter  The Pharma Letter Biogen Idec: A Great Company, But Not An Alpha Opportunity  Seeking Alpha Biogen/Samsung Approval of BYOOVIZ? | Goodwin - JDSupra  JD Supra Biogen launches new trial of Alzheimer's drug aducanumab  McKnight's Long Term Care News Biogen Idec Stock Hits New 52-Week High (BIIB)  TheStreet.com Biogen Alzheimer's drug in doubt after criticism from expert panel  Financial Times Cipla receives final approval for generic version of Biogen IDEC Inc.'s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack)  PRNewswire Baidu And Nvidia Lead The QQQ Lower Thursday - Benzinga  Benzinga Biogen Idec (NASDAQ: BIIB) will add 100 workers in North Carolina's Research Triangle Park  Triangle Business Journal Biogen Idec's Plegridy approved in Europe for relapsing-remitting multiple sclerosis  The Pharma Letter Biogen Inc. (BIIB) Stock Price Today, Quote & News  Seeking Alpha Biogen Idec's Strategy For Neurology RD Success  Life Science Leader Magazine Biogen Analysts Laud FDA Extension of Alzheimer's Drug Review  TheStreet Is Biogen Getting Desperate?  Motley Fool Biogen Idec (BIIB) shifts Machelle Sanders from head of RTP manufacturing to lead multiple sclerosis development - Triangle Business Journal  Triangle Business Journal Subcutaneous Biologics Market Market to See Huge Growth by 2030 | Abbott Laboratories, Pfizer Inc., Genentech Inc., Novartis AG, Biogen Idec  Medgadget FDA Accepts Biogen's BLA for Alzheimer's Candidate Aducanumab  Genetic Engineering & Biotechnology News Which Fund Has The Most To Gain From Biogen Idec?  Benzinga Biogen Idec to Acquire Stromedix  Business Wire Biogen Agrees to Pay $22 Million to Resolve Allegations that it Paid Kickbacks Through Two Co-Pay Foundations  Department of Justice Biogen Idec provides coach commuting for suburban workers  Boston Globe Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix  FierceBiotech Biogen Idec Moves Aggressively, Advances Alzheimer Drug InTo Phase 3  Clinical Leader Biogen Idec grabs Convergence, neuropathic pain portfolio in $675M buyout  FierceBiotech Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership  Business Wire Biogen Idec Moving HQ Back to Cambridge, Constructing Two New Buildings at Kendall Square  Xconomy Biogen Idec sets price for new MS pill  Boston Globe How Biogen Makes Money: Treatments for Neurological Disorders  Investopedia Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe  Business Wire Biogen Idec Trading Higher on 1.7x Above-Average Volume (BIIB) - Benzinga  Benzinga Profits up, Biogen cuts 11% of global workforce  Fortune Exclusive: Biogen prices hemophilia drug on par with older therapies  Reuters Biogen Idec Set to Join the S&P 100; Keurig Green Mountain to Join the S&P 500; Changes to the S&P MidCap 400 and the S&P SmallCap 600  PR Newswire UPDATED: Germany gives an initial 'no additional benefit' on Biogen Idec's Tecfidera  FiercePharma In dramatic turn, Biogen seeks FDA approval for experimental Alzheimer's drug  ABC News Biogen Idec, Atlas Venture Pump $17M into Ataxion  Genetic Engineering News ACADIA Pharma Shares Spike ~$0.90 Over Last Min, Now Pulling Back From Session Highs; Traders Circulating Chatter Of Biogen Interest  Benzinga Biogen Idec. chief executive to retire - The Boston Globe  Boston Globe Biogen Idec CEO Jim Mullen Stepping Down, After Tumultuous Year of Shareholder Activism  Xconomy Biogen to pay Forward Pharma $1.25 billion to protect MS drug  Reuters Biogen CEO has 'mixed emotions' as he leaves company after 6 years  CNBC Classen Immunotherapies, Inc. v. Biogen IDEC (Fed. Cir. 2011)  Patent Docs Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response - Benzinga  Benzinga Ataxion Announces $17M Series A Financing from Atlas Venture and Biogen Idec  Business Wire Biogen Must Face FCA Suit Minus 17 State-Level Claims  Law360 Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder  Xconomy
For more news about Biogen Idec Inc. click here:
Biogen Idec Inc. News
Search the Internet:

Website Width:
Bookmark and Share

 Background image:

Copyright@2010-2021 - TR4DER.com, all rights reserved.
Investment Forum Stock Quotes Investment News Investment Chat Disclaimer Webmaster Resources